Q-omics provides the consensus-scored RPL29P19 profile across patient tissues and cancer cell-line models. RPL29P19 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RPL29P19 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, RPL29P19 RNA expression shows 14,100 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, HNSC, and TGCT as cancer lineages where RPL29P19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL29P19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL29P19 survival associations across molecular data types. RPL29P19 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL29P19 RNA expression–survival associations across cancer types. High RPL29P19 expression shows unfavorable associations in KIRC, HNSC, BLCA, STAD and PAAD, but favorable associations in LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RPL29P19 RNA expression.
This table summarizes RPL29P19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL29P19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL29P19 shows lower tumor expression in KICH, KIRP and KIRC and higher tumor expression in HNSC, LUSC and THCA. The HNSC box plot shows higher RPL29P19 RNA expression in tumor versus normal tissue (log2 FC = +2.881, t-test p < 0.001).
This table shows molecular features associated with RPL29P19 in patient tissues and cancer cell lines. In patient samples, RPL29P19 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
